

# 2022 Interim Results

Hangzhou Tigermed Consulting Co., Ltd.

300347.SZ / 3347.HK

August 2022

www.tigermedgrp.com

## Disclaimer

This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2022 interim results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk) for further information.

#### All financials disclosed in this document are presented in accordance with International Financial Reporting Standards ("IFRS"s) except for those specifically noted otherwise.

By reading these materials, you agree to be bound by the following limitations:

The information herein has been prepared by representatives of Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格医药科技股份有限公司, the "Company") solely for your information and have not been independently verified. The information herein does not constitute any recommendation regarding any securities of the Company or any of its subsidiaries.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The Company, nor any of their respective affiliates, controlling persons, directors, officers, employees, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of the information herein or its contents or otherwise arising in connection with the information herein. The information or opinions set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially without notice and shall only be considered current as of the date hereof. The information herein is based on the economic, regulatory, market and other conditions as in effect on the date hereof. Certain information in the materials contain information may be sourced from third parties, which has not been independently verified by the Company. It should be understood that any subsequent developments may affect the information contained herein, which the Company is not under an obligation to update, revise or affirm.

You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company and any of its subsidiaries.

#### **Forward-Looking Statements**

The information communicated herein may contain certain "forward-looking statements", which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company or its subsidiaries will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.

#### **Non-IFRS Measure**


To supplement our financial information which are presented in accordance with IFRS, we use adjusted net profit attributable to owners of the Company as an additional financial measure, which is not required by, or presented in accordance with IFRS. We define adjusted net profit attributable to owners of the Company as profit for the year attributable to owners of the Company before certain expenses and amortization. We define adjusted net profit attributable to owners of the Company as profit for the year attributable to owners of the Company adjusted for (1) share-based compensation expense, (2) net foreign exchange loss/(gain) , (3) one-off expenses in relation to acquisitions, and (4) changes in fair value of financial assets at FVTPL. Adjusted net profit attributable to owners of the Company is not an alternative to (i) profit before tax, profit for the year or profit for the year attributable to owners of the Company (as determined in accordance with IFRS) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs, or (iii) any other measures of performance or liquidity. We believe that this non-IFRS measure is useful for understanding and assessing underlying business performance and operating trends, and that the owners of the company and we may benefit from referring to this non-IFRS measure in assessing our financial performance of our business. However, the presentation of this non-IFRS measure is not intended to, and should not, be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS measure on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results or a similarly titled financial measure reported or forecasted by other companies.




# 01 Results Overview



## 1H2022 Key Financials




## Revenue Breakdown by China and Overseas Markets






## **Cost of Services**





## **Operating Expenses**






# 02 Business Updates

**Clinical Trial Solutions** 




## Clinical Trial Solutions ("CTS")






## **CTS Key Business Updates**




#### Number of Ongoing Drug Clinical Research Projects by Region<sup>(1)</sup>





### **Overseas Clinical Operation Business Updates**




- **149** ongoing single region overseas clinical trials as of June 30, 2022, primarily in South Korea, Australia and the United States
- **58** ongoing MRCTs as of June 30, 2022
- 26 overseas subsidiaries as of June 30, 2022 and have set up new subsidiaries in UK, Netherland and Vietnam in 1H2022
- Overseas employees in **53** countries across **five** continents as of June 30, 2022
- Acquired 50+ new bookings for overseas clinical trial and registration projects in 1H2022
- 152 Global Project Managers from 19 countries successfully completed tailor-made Alumni PM trainings in 1H2022

Industry Leadership in the Clinical Service Market

Tigermed has the largest market share of **12.5%** in China's clinical outsourcing market in 2021, up by 4.1% from 2019<sup>(1)</sup>

Tigermed is the only China-based clinical service provider ranked among global top 10 with a **1.3%** market share in 2021, up by 0.5% from 2019<sup>(1)</sup>



Tigermed team enabled successful approvals of 4 China Class I innovative drugs in 1H 2022

56.6%

provided services to **56.6%** of all Class I innovative drug approvals in China from 2016 to 1H2022

Tigermed served the largest amount of HGRAC clinical research filling projects as contract research organization (CRO) in 2021-1H2022<sup>(2)</sup>

12.5%

acounted for **12.5%** of total HGRAC clinical research filing projects in 2021-1H2022<sup>(2)</sup>



(1) Source: Frost & Sullivan; revenue used for calculation of market share in China includes clinical-related revenue from China subsidiaries for multinational CROs and total clinical-related revenue for China-based CROs; clinical-related revenue for Tigermed excludes revenue generated from laboratory services; 1 USD = 6.4517 RMB

(2) Source: Human Genetic Resource Administration of China (HGRAC) website, might not be exhaustive; a total of 4,040 filings between January 1, 2021 and June 30, 2022, of which 2,040 filings with clinical CRO involvement; filings refer to international collaboration filings including both filings for approvals (审批) and filings for records (备案); includes all controlled subsidiaries of Tigermed and there maybe be one or more than one Tigermed projects that could not be captured from the HGRAC website

### Positioned to further enhance decentralized trial management and risk-based monitoring capabilities





All clinical trial procedures are conducted at clinical sites (e.g. hospitals)

- Tailinyan (泰临研) platform offers multi-scenario solutions to patients, sponsors, clinical sites and CROs
- Platform features multifaceted remote monitoring capability to address different decentralized trial environments
- Over 800 pharmaceutical or biotech companies have used Tailinyan platform with more than 3,000 clinical trials, of which over 80 are large-scale Phase III pivotal trials<sup>(1)</sup>





Less complex clinical trial procedures are conducted remotely Further advancement in digital technology and direct-to-patient supply delivery could allow all clinical trial procedures conducted virtually

- Enhanced patient experience
- Increased monitoring coverage
- Improved project management efficiency
- Better cost control

#### Conventional On-site Monitoring



Heavy reliance on physical source data verification Large amount of data Huge workload Higher risk of inaccuracy and inconsistency Higher internal resource uptake Lack of cross-site collaboration

- Risk-Based Quality Management ("RBQM") platform further expanded:
  Study level: Quality monitoring based on Quality Tolerance Limits (QTL)
  - Study level: Project overview based on study endpoints
  - Site level: Risk monitoring based on key risk indicators
  - Data level: Data quality evaluation based on statistical monitoring
  - Data level: Medical monitoring based on data visualization
- Continued to optimize RBQM platform and operating procedures with the introduction of multiple SOPs and core tools in 1H2022, including in-house Risk Assessment and Categorization Tool ("RACT")
- Finalizing Phase II Project for RBQM platform development with enhanced risk monitoring capability based on key risk indicators<sup>(1)</sup>

#### Risk-based Centralized Monitoring



Better efficiency Lower cost Higher flexibility Robustness of results Consistency of data Allows cross-site comparison



#### Medical Device Clinical Research

- Had **403** ongoing medical device projects<sup>(1)</sup> as of June 30, 2022
- Our medical device business ranked 2<sup>nd</sup> in China's medical device outsourcing market with a 7.1% market share, and ranked 1<sup>st</sup> in China's medical device clinical research and registration market <sup>(2)</sup>
- Expanded medical device data management and statistical analysis talent pool in 1H2022 as one of the largest dedicated for medical device studies; continued collaborations with the School of Health Management of China Medical University to offer professional data management trainings
- Invested in building lifecycle management capability for digital therapeutics in 1H2022 on the back of burgeoning R&D activities in this area
- Led the drafting work of two group standards for medical device quality system in 1H2022

### Regulatory Affairs

- Number of customers of our regulatory affair services increased to 582 as of June 30, 2022 from 550 as of December 31, 2021
- A total of **1,124** accumulated project experience as of June 30, 2022
- Number of new US FDA-related projects increased by 67% year-over-year in 1H2022
- Assisted regulatory filings of multiple MRCTs in over 20 countries including various emerging markets with multiple successful IND approvals obtained



### Pharmacovigilance ("PV") and Real World Studies

- Added **177** new PV projects in 1H2022
- Size of Tigermed PV team reached **128** as of June 30, 2022
- Formally launched our in-house developed **eCPM**<sup>(1)</sup> system in 1H2022, a patient-centric real world study management platform that can support multiple projects simultaneously. Our eCPM system focuses on functionality and encompasses patient consent/tele-consent, patient management, follow-ups, real world project management and other scenarios that are key for the project management and execution of our real world studies. This system is also designed modularly and can be tailored for different real world studies
- Continued to gain new real world studies in 1H2022 from both local and multinational pharmaceutical and medical device customers
- Formed collaboration with Shanghai Ruijin Hainan Hospital (上海瑞金医院海南医院) in Boao Lecheng Clinical Center

### **Medical Translation**

- Added 28 new customers for our medical translation services in 1H2022, including 12 pharmaceutical companies and 16 medical device companies; top medical translation customers include top multinational pharmaceutical and medical device companies
- Medical translation services cover 33 languages in Europe and Americas and 14 languages in Southeast Asia as of June 30, 2022
- Continued to upgrade our centralized medical translation platform in 1H2022 by integrating in-house developed translation production portal with project management platform to further improve the efficiency
- Medical translation business unit obtained **ISO14001** certificate in 1H2022
- Ranked 57<sup>th</sup> globally (5<sup>th</sup> in Chinese Mainland and 15<sup>th</sup> in Asia Pacific) in 2022 CSA Research Largest Language Service Providers Ranking<sup>(2)</sup>




# 03 Business Updates

Clinical-related and Lab Services




## Clinical-related and Lab Services ("CRLS")





## **CRLS Key Business Updates**

## Project Status for Key CRLS Services




Tigermed

Data Management & Statistical Analysis ("DMSA")

- DMSA team had 786 ongoing projects as of June 30, 2022, of which 526 projects were being conducted by our team based in China and 260 projects by team based overseas
- Total number of customers increased to **208** as of June 30, 2022 from 163 as of December 31, 2021
- As of June 30, 2022, DMSA team had more than **840** professionals based in China, South Korea, the United States and India
- Initiated a new DMSA site at Luohe, Henan in 1H2022 as part of our continuing effort to increase operating efficiency, expanding both data management and statistical analysis team there
- Launched **DMSA digital solutions** in February 2022, including four modules for data management and five for statistical analysis

# We are the largest DMSA service provider in China with **13.4%** market share



#### Laboratory Services

- Expanded capacities in pharmacological safety assessment and toxicology services through the acquisition of Experimur (US), and further expanded our bioanalytical, biologics bioassay, and biomarker services through new **25,000** sq. ft. facility in Hayward, CA
- The new 67,000 sq. ft. bioanalytical, central lab and DMPK facility, as well as a 7,000 sq. ft. GMP kilo laboratory and a 17,000 sq. ft. medicinal chemistry facility in Shanghai were fully operational. The new 215,000 sq. ft. DMPK and non-GLP/GLP tox facility in Suzhou, and a new 34,000 sq. ft. drug screening facility in Wuhan became operational in 1H2022
- Frontage's toxicology facility in Suzhou, China was granted "Experimental Animal Use License" in January 2022 following authorities inspection of its first animal laboratory in China
- Laboratory services headcount increased from 1,322 as of December 31, 2021 to 1,505 as of June 30,2022

#### Site Management

- Added **217** new projects in 1H2022 and had **1,469** ongoing site management projects as of June 30, 2022
- Team size of 2,503 with 2,108 full time Clinical Research Coordinators ("CRC"s) as of June 30, 2022, covering 140+ cities across China
- Adopted contingency plan for the COVID-19 outbreak in 1H2022 to reduce the impact on trial progress or quality by, where applicable, assisting patients to physically visit hospitals, couriering investigational drugs, and assigning CRCs residing at trial center to assist follow-ups
- Dynamically adjusted recruitment plans in light of the COVID-19 pandemic in 1H2022 to control budget and avoid redundancy and unnecessary costs

### Excellence for Clinical Trial Sites ("E-Site")


- E-Site Program had 19 regions across China, 164 E-Site centers and 67 Core centers as of June 30, 2022
- As of June 30, 2022, established strategic collaboration relationship with 21 E-Site centers to jointly explore and establish industry leading clinical research management platform and clinical lifecycle management capability
- Invited 31 experts and assisted to organize 14 regional conferences within E-Site network in 1H2022



# 04 Other Updates



## Updates of Investment Activities




- Portfolio included 146 companies in the healthcare industry and 57 investment funds as of June 30, 2022
- RMB **9,713.3** mm balance as of June 30, 2022
- Invested RMB 340.8 mm in unlisted equities; and RMB 152.1 mm in investment funds in 1H2022
- Received RMB **321.2** mm cash from investment exits in 1H2022
- In 1H2022, we realized a gain of RMB 80.7 mm from exiting our portfolio companies and funds, as measured by the exit amount against our initial investment cost



## Employee Base

#### Total employees decreased by 0.3% to 8,299 as of June 30, 2022 from 8,326 as of December 31, 2021





## **Commitment to Sustainability**

## AAA in 2022 CNI ESG Ratings by Shenzhen Stock Exchange

- In July 2022, Shenzhen Stock Exchange ("SZSE") officially launched CNI ESG Ratings Methodology and released ESG indices and ESG leading indices of SZSE's core indices (Shenzhen Component Index, ChiNext Index, Shenzhen 100) that were compiled based on the methodology
- The CNI ESG Ratings Methodology aims to provide ESG rating tools that are suitable for the Chinese capital market. Underpinned by environment, corporate social responsibilities and corporate governance, CNI ESG Ratings aims to reflect the sustainable development practices and achievements of SZSE-listed companies. Tigermed was rated AAA, the highest ranking of the CNI ESG Ratings





## Enhanced Corporate Branding in 1H2022

#### Mission

Advance human health through delivery excellence

#### Vision

To be recognized as the leading global CRO

#### Values

Honesty, Accountability Respect, Partnership

#### **Brand Identity**

Passion for Innovation Global Excellence, China Expertise








## Global and China Pharmaceutical R&D Service Market By R&D Stage, 2017-2026E


#### Global CRO Market Size<sup>(1)</sup>

Time Devied	CAGR			
Time Period	Discovery	Preclinical	Clinical	Overall
2017-2021	10.4%	8.3%	9.7%	9.6%
2021-2026E	15.6%	10.6%	9.2%	10.8%

UD\$bn



#### China CRO Market Size<sup>(2)</sup>





## **Consolidated Statement of Profit or Loss**

	Period ended June 30,		
(RMB 000s)	2021	2022	
Revenue	2,056,375	3,594,209	
Cost of services	(1,089,456)	(2,175,881)	
Gross profit	966,919	1,418,328	
Other income	147,419	128,757	
Other gains and losses, net	1,007,221	468,609	
Impairment losses	(10,252)	(28,411)	
Selling and marketing expenses	(66,656)	(80,040)	
Administrative expenses	(246,682)	(321,379)	
Research and development expenses	(93,034)	(110,520)	
Share of losses of associates	723	35,556	
Finance costs	(7,942)	(31,035)	
Profit before tax	1,697,716	1,479,865	
Income tax expense	(103,533)	(162,239)	
Profit for the year	1,594,183	1,317,626	
Profit attributable to owners of the Company	1,259,914	1,192,004	
Adjusted for:			
Share-based compensation expense	33,369	16,673	
Net foreign Exchange loss/(gain)	3,471	(1,829)	
One-off expenses in relation to acquisitions	4,344	17,225	
Change in fair value of financial assets at FVTPL	(609,005)	(347,542)	
Adjusted net profit attributable to owners of the Company <sup>(1)</sup>	692,093	876,531	

## **Consolidated Statement of Financial Position**

(RMB 000s)	As of December 31, 2021	As of June 30, 2022
NON-CURRENT ASSETS	12,891,285	14,993,243
Property, plant and equipment	701,857	824,671
Intangible assets	234,090	271,738
Goodwill	1,778,948	2,347,881
Right-of-use assets	473,262	477,068
Interests in associates	738,799	1,227,541
Deferred tax assets	100,936	98,011
Financial assets at fair value through profit or loss ("FVTPL")	8,746,344	9,677,705
Financial assets at fair value through other comprehensive income ("FVTOCI")	13,531	-
Restricted bank deposits	1,913	2,013
Other non-current assets	101,605	66,615
CURRENT ASSETS	10,849,888	10,709,937
Inventories	6,095	16,965
Trade, bills and other receivables and prepayments	952,017	1,053,818
Contract assets	1,285,475	1,765,802
Structured deposits and derivative financial instruments	29,180	35,569
Prepaid income tax	34,678	64,861
Restricted bank deposits	8,586	8,046
Time deposit with original maturity over three months	155,440	67,479
Cash and cash equivalents	8,378,417	7,697,397



## Consolidated Statement of Financial Position (Cont'd)

(RMB 000s)	As of December 31, 2021	As of June 30, 2022
CURRENT LIABILITIES	2,412,716	3,434,473
Trade and other payables	879,962	632,059
Contract liabilities	789,509	819,623
Borrowings	492,320	1,761,905
Income tax payables	176,410	135,102
Lease liabilities	74,515	85,784
NON-CURRENT LIABILITIES	723,260	771,800
Non-current Bank borrowing		37,492
Deferred government grant	<u> </u>	14,459
Lease liabilities	406,839	408,150
Other long-term liabilities	114,881	98,654
Deferred tax liabilities	201,540	213,045
NET ASSETS	20,605,197	21,496,907
TOTAL EQUITY	20,605,197	21,496,907
Share capital	872,439	872,419
Treasury shares	(579,186)	(869,340)
Reserves	17,892,210	18,702,353
Equity attributable to owners of the Company	18,185,463	18,705,432
Non-controlling interests	2,419,734	2,791,475





# 300347.SZ/3347.HK

Hangzhou Tigermed Consulting Co., Ltd. www.tigermedgrp.com